# molab.ai

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/molab-ai

- Industry: Biotechnology
- Headquarters: Munich, Germany
- Website: www.molab.ai/
- Latest round: Seed (May 16, 2022)
- Investors on record: 1

## About

Based in Munchen, Germany, and founded in 2022, molab.ai GmbH is a biotechnology research company that uses artificial intelligence to create precision molecules used for drug discovery and research. In July 2025, Cresset, a portfolio company of Scottish Equity Partners, acquired molab.ai GmbH from Picus Capital.

The firm offers an end-to-end drug discovery platform, featuring in-silico design, an ADMET prediction engine, and a compound optimization suite that provides AI-based (artificial intelligence) actionable recommendations that reduce the hit-to-lead and lead optimization projects. The platform provides technology solutions to create molecular structures, enhancing their potency and selectivity, for applications such as in vivo ADME, toxicity, and physiochemical properties.

## Funding rounds

- Seed, May 16, 2022 — Picus Capital

## Investors

- Picus Capital (https://capitalatlas.ai/funds/picus-capital) — Seed